HIV Fusion Inhibitors

Inhibitors of the fusion of HIV to host cells, preventing viral entry. This includes compounds that block attachment of HIV ENVELOPE PROTEIN GP120 to CD4 RECEPTORS.
Also Known As:
HIV Cell Fusion Inhibitors; Entry Inhibitors, HIV; Fusion Inhibitors, HIV; HIV Entry Inhibitors
Networked: 20 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results


1. Fujii, Nobutaka: 3 articles (01/2007 - 07/2004)
2. Tamamura, Hirokazu: 3 articles (01/2007 - 07/2004)
3. Balzarini, Jan: 2 articles (09/2012 - 05/2005)
4. Jiang, Shibo: 2 articles (08/2009 - 01/2002)
5. Masuno, Hiroyuki: 2 articles (01/2007 - 01/2007)
6. Hiramatsu, Kenichi: 2 articles (01/2007 - 07/2004)
7. Tsutsumi, Hiroshi: 2 articles (01/2007 - 01/2007)
8. Esté, José A: 2 articles (01/2004 - 09/2003)
9. Vere Hodge, R Anthony: 1 article (11/2015)
10. Liwang, Patricia J: 1 article (09/2012)

Related Diseases

1. HIV Infections (HIV Infection)
2. Acquired Immunodeficiency Syndrome (AIDS)
3. Neoplasms (Cancer)
4. Infection
08/01/2009 - "Therefore, these findings strongly imply that, rather than replacing T20, combining it with HIV fusion inhibitors of different generations might produce synergistic activity against both T20-sensitive and -resistant HIV-1 strains, suggesting a new therapeutic strategy for the treatment of HIV-1 infection/AIDS."
09/01/2011 - "HIV entry inhibitors, including CCR5 antagonists, are clinically used for the treatment of this viral infection; the compounds claimed in the patent, possessing a new and original scaffold, seem to be of interest for developing novel antiviral agents belonging to this class."
03/01/2010 - "HIV entry inhibitors, TAK779 and AMD3100, blocked HIV infection of PMs, indicating that infection by R5 and X4 strains was mediated by CCR5 and CXCR4, respectively. "
01/01/2007 - "Therefore, we evaluated HIV entry inhibitors (EIs) and reverse transcriptase inhibitors (RTIs) for their ability to block cell-free and cell-associated HIV-1 infection in co-cultures of monocyte-derived dendritic cells (MO-DC) and CD4+ T-cells using settings of pre- and post-exposure prophylaxis. "
05/01/2005 - "They inhibit HIV-1 infection at a 50% effective concentration of 0.2 to 0.3 microg/ml. Escalating HHA or GNA concentrations (up to 500 microg/ml) led to the isolation of three HIV-1(III(B)) strains in CEM T cell cultures that were highly resistant to HHA and GNA, several other related mannose-specific plant lectins, and the monoclonal antibody 2G12, modestly resistant to the mannose-specific cyanovirin, which is derived from a blue-green alga, but fully susceptible to other HIV entry inhibitors as well as HIV reverse transcriptase inhibitors. "
5. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

Related Drugs and Biologics

1. T140 peptide
2. HIV Reverse Transcriptase
3. Peptides
4. Mannose (D-Mannose)
5. enfuvirtide (Fuzeon)
6. Anti-Retroviral Agents (Antiretroviral Agents)
7. Plant Lectins
8. Anti-HIV Agents (AIDS Drugs)
9. Reverse Transcriptase Inhibitors
10. Protease Inhibitors (Protease Inhibitor)